Novartis' Ultibro® Breezhaler® improved lung function and COPD symptoms after direct switch from previous treatment

Novartis International AG / Novartis' Ultibro® Breezhaler® improved lung function and COPD symptoms after direct switch from previous treatment . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.Ultibro ®...

London, 08/12/2016 (informazione.it - comunicati stampa - salute e benessere)